EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome

Taishi Nada, Koichi Kamei, Keigo Sasaki, Kentaro Nishi, Yu Kamigaki, Toru Uchimura, Aya Inaba, Masao Ogura, Shuichi Ito

Pediatric Nephrology · 2026

DOI: 10.1007/s00467-026-07397-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Nephrology, 2026. Verfasst von Taishi Nada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Mycophenolic Acid, Nephrotic Syndrome, Rituximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear.

Methods

We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed.

Results

Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan–Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05).

Conclusions

Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsMycophenolic AcidNephrotic SyndromeRituximabAdolescentChildChild, PreschoolFemaleHumansMaleDrug Therapy, CombinationImmunologic FactorsKaplan-Meier EstimateMaintenance ChemotherapyRecurrenceRemission InductionRetrospective StudiesRisk FactorsSecondary PreventionTreatment InterruptionTreatment Outcome

Stichwörter der Autor:innen

ChildrenDiscontinuationMycophenolate mofetilNephrotic syndromeRituximab

Substanzen

Immunologic FactorsImmunosuppressive AgentsMycophenolic AcidRituximab

Autor:innen und Institutionen

  • Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Yokohama City University Medical Center, Kanagawa, Japan.
  • Department of Nephrology, Kanagawa Children's Medical Center, Kanagawa, Japan.
  • Department of Pediatrics, Yokohama Minami Kyousai Hospital, Kanagawa, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. itoshu@yokohama-cu.ac.jp.

Zitieren

APA

Nada, T., Kamei, K., Sasaki, K., Nishi, K., Kamigaki, Y., Uchimura, T., Inaba, A., Ogura, M., & Ito, S. (2026). Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome. Pediatric Nephrology. https://doi.org/10.1007/s00467-026-07397-1

Vancouver

Nada T, Kamei K, Sasaki K, Nishi K, Kamigaki Y, Uchimura T, et al. Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome. Pediatric Nephrology. 2026. doi:10.1007/s00467-026-07397-1

BibTeX
@article{Nada2026,
  author = {Nada, Taishi and Kamei, Koichi and Sasaki, Keigo and Nishi, Kentaro and Kamigaki, Yu and Uchimura, Toru and Inaba, Aya and Ogura, Masao and Ito, Shuichi},
  title = {Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome},
  journal = {Pediatric Nephrology},
  year = {2026},
  doi = {10.1007/s00467-026-07397-1}
}
Kostenlos starten →